Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Therapeutic Advances in Neurological Disorders 9.4 (2016): S. 269-280.
- Schlagwort
-
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Ereignis
-
Veröffentlichung
- (wo)
-
Erlangen
- (wer)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (wann)
-
2016
- Urheber
-
Utz, Kathrin S.
Lee, De-Hyung
Lämmer, Alexandra
Waschbisch, Anne
Linker, Ralf A.
Schenk, Thomas
- URN
-
urn:nbn:de:bvb:29-opus4-90485
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:47 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Utz, Kathrin S.
- Lee, De-Hyung
- Lämmer, Alexandra
- Waschbisch, Anne
- Linker, Ralf A.
- Schenk, Thomas
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Entstanden
- 2016
Ähnliche Objekte (12)
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Evaluation and further development of handbooks explaining different disease-modifying therapies for people with multiple sclerosis (MS)
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets
Studies on pathomechanisms and novel therapies in amyotrophic lateral sclerosis
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Modifying adjuncts
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Modifying branched surfaces
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Evaluation and further development of handbooks explaining different disease-modifying therapies for people with multiple sclerosis (MS)
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets
Studies on pathomechanisms and novel therapies in amyotrophic lateral sclerosis
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Modifying adjuncts
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Modifying branched surfaces
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Evaluation and further development of handbooks explaining different disease-modifying therapies for people with multiple sclerosis (MS)
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets
Studies on pathomechanisms and novel therapies in amyotrophic lateral sclerosis
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Modifying adjuncts
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Medication beliefs in first-line and second-line treated multiple sclerosis patients